Dr. William V. Walsh
Claim this profileUMass Memorial Medical Center - University Campus
Area of expertise
Lung Cancer
William V. Walsh has run 18 trials for Lung Cancer. Some of their research focus areas include:
Non-Small Cell Lung Cancer
William V. Walsh has run 12 trials for Non-Small Cell Lung Cancer. Some of their research focus areas include:
Affiliated Hospitals
UMass Memorial Medical Center - University Campus
Simonds-Sinon Regional Cancer Center
Clinical Trials William V. Walsh is currently running
Osimertinib + Bevacizumab
for Lung Cancer
This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.
Recruiting
2 awards
Phase 3
31 criteria
Dostarlimab
for Head and Neck Cancer
The goal of this study is to assess the safety and effectiveness of Dostarlimab compared to Placebo in adult participants with Head and Neck Squamous Cell Carcinoma (HNSCC)
Recruiting
1 award
Phase 3
More about William V. Walsh
Clinical Trial Related
5 years of experience running clinical trials · Led 23 trials as a Principal Investigator · 8 Active Clinical Trials
Treatments William V. Walsh has experience with
- Carboplatin
- Pembrolizumab
- Pemetrexed
- Cisplatin
- Paclitaxel
- Atezolizumab
Breakdown of trials William V. Walsh has run
Lung Cancer
Non-Small Cell Lung Cancer
Lung Carcinoma
Squamous Cell Carcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does William V. Walsh specialize in?
William V. Walsh focuses on Lung Cancer and Non-Small Cell Lung Cancer. In particular, much of their work with Lung Cancer has involved Stage IV patients, or patients who are Stage III.
Is William V. Walsh currently recruiting for clinical trials?
Yes, William V. Walsh is currently recruiting for 8 clinical trials in Worcester Massachusetts. If you're interested in participating, you should apply.
Are there any treatments that William V. Walsh has studied deeply?
Yes, William V. Walsh has studied treatments such as Carboplatin, Pembrolizumab, Pemetrexed.
What is the best way to schedule an appointment with William V. Walsh?
Apply for one of the trials that William V. Walsh is conducting.
What is the office address of William V. Walsh?
The office of William V. Walsh is located at: UMass Memorial Medical Center - University Campus, Worcester, Massachusetts 01655 United States. This is the address for their practice at the UMass Memorial Medical Center - University Campus.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.